产品说明
一般描述
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
生化/生理作用
FTY720是一种免疫调节药物以及1-磷酸鞘氨醇(S1P)受体的调节剂。 鞘氨醇激酶对FTY270的磷酸化可导致S1P1R的内化，从而螯合淋巴结中的淋巴细胞，阻止它们参与自身免疫反应。 临床上，它已被批准用于治疗多发性硬化症(MS)。研究显示其可通过抑制S1PR阻断和逆转紫杉醇诱导的化疗诱导的周围神经病变(CIPN)，并可抑制小鼠脑海马中组蛋白脱乙酰酶的活性，从而调节记忆。
分析说明
These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.
其他说明
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
附注
To see an example of a Certificate of Analysis for this material enter LRAC6340 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.
基本信息
| 经验(实验)分子式 | C19H33NO2 · HCl |
| 分子量 | 343.93 |
产品性质
| 等级 | certified reference material pharmaceutical secondary standard |
| 描述 | Pharmaceutical Secondary Standard; Certified Reference Material |
| 形式 | powder |
| 包装 | pkg of 500 mg |
| 药典可追溯性 | traceable to PhEur Y0002055 traceable to USP 1270480 |
| 储存温度 | 2-30℃ |
| InChI | 1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H |
| InChI key | SWZTYAVBMYWFGS-UHFFFAOYSA-N |
安全信息
| 象形图 |  |
| 警示用语： | Warning |
| 危险声明 | H373 |
| 预防措施声明 | P260 - P314 - P501 |
| 危险分类 | STOT RE 2 |
| 靶器官 | Immune system |
| 储存分类代码 | 11 - Combustible Solids |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
